CHASKA, Minn. — August 7, 2025 — Leads & Copy — Lifecore Biomedical, Inc. (NASDAQ: LFCR) today announced its financial results for the fourth quarter and fiscal year 2025, reporting $128.9 million in revenue, meeting full-year guidance. The company signed nine new programs with new customers during the fiscal year, reflecting growth into modalities beyond ophthalmic therapeutics.
Lifecore’s President and CEO, Paul Josephs, noted the company’s restructuring and efficiency improvements during fiscal 2025, including headcount adjustments and expense reductions as a percentage of revenue. The company also progressed its late-stage pipeline and added multiple new customers.
For the remainder of calendar year 2025, Lifecore expects revenue to be approximately $74 to $76 million.
Key financial highlights include:
- Revenues: $36.4 million for the quarter, $128.9 million for the year.
- Gross Profit: $14.0 million for the quarter, $40.3 million for the year.
- Net Loss: $1.1 million for the quarter, $38.7 million for the year.
Lifecore will host a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. The webcast can be accessed via Lifecore’s Investor Events & Presentations page.
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO).
Contact Information:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com
Source: Lifecore Biomedical, Inc.
